ADReCS

Pharmaceutical Information

Drug Name	Saxagliptin
Drug ID	BADD_D01992
Description	Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Indications and Usage	Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Marketing Status	approved
ATC Code	A10BH03
DrugBank ID	DB06335
KEGG ID	D08996
MeSH ID	C502994
PubChem ID	11235729
TTD Drug ID	D0K9MY
NDC Product Code	50193-4212; 0310-6100; 0310-6105; 11722-078; 0310-7100; 50370-0030; 55154-6931; 0310-7105
UNII	9GB927LAJW
Synonyms	saxagliptin \| 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate \| Onglyza \| BMS 477118 \| BMS477118 \| BMS-477118

Chemical Information

Molecular Formula	C18H25N3O2
CAS Registry Number	361442-04-8
SMILES	C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Dehydration	14.05.05.001	0.001211%
Dermatitis	23.03.04.002	-	-	-
Dermatitis exfoliative	10.01.01.004; 23.03.07.001	-	-
Diabetes mellitus inadequate control	05.06.01.004; 14.06.01.004	0.001048%		-
Dizziness	02.11.04.006; 17.02.05.003; 24.06.02.007	0.002815%
Drug eruption	08.01.06.015; 10.01.01.005; 23.03.05.001	0.000720%		-
Drug interaction	08.06.03.001	0.001211%		-
Dysgeusia	07.14.03.001; 17.02.07.003	0.000720%
Dyspepsia	07.01.02.001	0.000720%
Dysphagia	07.01.06.003	0.002095%
Face oedema	08.01.07.003; 10.01.05.002; 23.04.01.004	-	-
Fatigue	08.01.01.002	-	-
Flatulence	07.01.04.002	-	-
Fluid retention	14.05.06.002; 20.01.02.003	0.001670%		-
Fracture	12.04.02.001; 15.08.02.001	-	-
Gait disturbance	08.01.02.002; 15.03.05.013; 17.02.05.016	0.000327%
Gastritis	07.08.02.001	-	-
Gastroenteritis	07.19.03.001; 11.01.07.004	-	-	-
Gastrointestinal disorder	07.11.01.001	-	-	-
Gastrointestinal pain	07.01.05.005	-	-
Headache	17.14.01.001	-	-
Hepatic function abnormal	09.01.02.001	0.000655%		-
Hepatocellular injury	09.01.07.008	0.000327%		-
Hyperglycaemia	05.06.02.002; 14.06.02.002	0.001211%
Hypersensitivity	10.01.03.003	-	-
Hypertriglyceridaemia	14.08.02.001	-	-
Hyperuricaemia	14.09.01.003	0.000327%
Hypocalcaemia	14.04.01.004	0.000491%
Hypoglycaemia	05.06.03.001; 14.06.03.001	0.001931%
Hypoglycaemic coma	05.06.03.004; 14.06.03.004; 17.02.09.005	0.000491%		-

The 2th Page First Pre 2 3 4 5 Next Last Total 5 Pages